| 1 | Microplate chemiluminescence enzyme immunoassay for the quantitative evaluation of carbohydrate antigen 72-4 in human serum显示文摘A highly sensitive and specific microplate chemiluminescence enzyme immunoassay (CLEIA) was developed for the quantitative evaluation of carbohydrate antigen 72-4 (CA72-4) in human serum, using luminol-H2O2 catalyzed by horseradish peroxidase (HRP) as the chemiluminescence system. The simple and quick determination was accomplished through a sandwich reaction mode. Several physico-chemical parameters of the immunoreaction, including incubation conditions, antibody coating conditions, dilution ratio of anti-CA72-4-HRP conjugate, and chemiluminescence reaction time, were studied and optimized. The proposed method exhibited a linear range of 0―200 U/mL with correlation coefficient and detection limit of 0.9995 and 0.18 U/mL, respectively. The inter-assay and intra-assay coeffi-cients of variation (CV) were both less than 10%. The average recovery of two clinical sera with low and high concentration CA72-4 was 99.3% and 98.7%, respectively. Normal tumor markers, including AFP, CEA, CA24-2, CA19-9 and CA15-3, did not cross-react with each other. The method's stability was evaluated by assessing its analytical performance after storing the immunoreagents at 4℃ and 37℃ for 7 days. Little difference was found, indicating satisfactory stability of the method. The present method has been successfully applied to the detection of CA72-4 human serum, and showed a good correlation with the commercially available ELISA kit (r 2=0.9383). This method showed great potential in the fabrication of diagnostic kit for CA72-4, and could be well used in diagnosis of cancer in clinical practice. | JIN Hui WANG Xu XIN TianBing GAO Peng LIN Jin-Ming LIANG ShuXuan | 2008 | Chinese Science Bulletin2008，53，19： | 2 |
| 2 | Ultrasonic Characteristics and Severity Assessment of Lung Ultrasound in COVID-19 Pneumonia:A Retrospective,Observational Study显示文摘The clinical application of lung ultrasound(LS)in the assessment of coronavirus disease 2019(COVID-19)pneumonia severity remains limited,Herein,we investigated the role of LUS imaging in CoVID-19pneumonia patients and the relationship between LUS findings and disease severity.This was a retro-spective,observational study at Tongji Hospital,on 48 recruited patients with COVID-19 pneu-monia,including 32 non-critically ill patients and 16critically ill patients.LUS was performed and the respiratory rate oxygenation(ROX)index,disease severity,and confusion,blood urea nitrogen,respira-tory rate,blood pressure,and age(CURB-65)score were recorded on days 0-7,8-14,and 15-21 after symptomonset.Lung images were divided into 12 regions,and the luS score(0-36 points)was calcu-lated.hestcomputed tomography(CT)scores(0-20 points)were also recorded on days O-7.Coelations between the LUS score,ROX index,and CURB-65 scores were examined.LUS detected COVID-19 pneumonia in 38patients.LUS signs included B lines(34/38,89.5%),consolidations(6/38,15.8%),and pleural effusions(2/38,5.3%).Most cases showed more than one lesion(32/38,84.2%)and involved both lungs(28/38,73.7%).Compared with non-critically ill patients,the LUS scores of critically ill patients were higher(12(10-18)vs 2(0-5),p<0.001).The LUS score showed significant negative cor-relations with the ROX indexon days O-7(r=-0.85,p<0.001),days 8-14(r=-0.71,p<0.001),and days 15-21(r=-0.76,p<0.001)after symptom onset.However,the LUS score was positively correlated with the CT score(r=0.82,p<0.001).The number of patients with LUS-detected lesions decreased from 27 cases(81.8%)to 20 cases(46.5%),and the lus scores significantly decreased from 4(2-10)to 0(0-5),(p<0.001) from days O-7 to 17-21.We conclude that LUS can detect lunglesions in COVID-19 pneumo-nia patients in a portable,real-time,and safe manner.Thus,LUS is helpful in assessing COVID-19 pneu-monia severity in critically ill patients. | Fengxue Zhu Xiujuan Zhao Tianbing Wang Zhenzhou Wang Fuzheng Guo Haiyan Xue Panpan Chang Hansheng Liang Wentao Ni Yaxin Wang Lei Chen Baoguo Jiang | 2021 | Engineering2021，7，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员